Saturday 17 October 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
In the quarter to June 2026, EPS grew 58.7% and free cash flow fell 24.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.33
0.06
−1.37%
Follow CING
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 528.00 | 159.36 | 22.80 | 1.80 | 3.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 1,236.00 | 753.60 | 463.20 | 106.80 | 6.01 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 13 | 16 | 15 | 13 | 13 | 14 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (12) | (7) | (21) | (18) | (24) | (17) | (22) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (12) | (7) | (21) | (18) | (24) | (17) | (22) | |||||
| Depreciation | — | — | — | 0 | 1 | 1 | 0 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (10.93) | (12.70) | (669.87) | (374.55) | (312.12) | (10.20) | (4.44) | |||||
| Cash flow | — | — | — | (8.34) | (12.04) | (337.63) | (316.39) | (200.46) | (12.10) | (3.41) | |||||
| Capex | — | — | — | 0.00 | (0.71) | (26.37) | (3.06) | (2.99) | (0.14) | (0.03) | |||||
| Free cash flow | — | — | — | (8.34) | (12.76) | (364.00) | (319.45) | (203.45) | (12.24) | (3.44) | |||||
| Book value | — | — | — | 0.58 | 2.29 | 674.55 | 77.33 | (91.59) | 4.89 | 0.50 | |||||
| Shares, m | — | — | — | 1 | 1 | 0 | 0 | 0 | 2 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (9) | (7) | (10) | (16) | (15) | (18) | (17) | ||||
| Capex | — | — | — | (1) | 0 | (1) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (9) | (7) | (11) | (16) | (15) | (19) | (17) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (2) | (2) | 18 | 1 | (10) | 8 | 2 | ||||
| Total debt | — | — | — | 2 | 0 | 0 | 0 | 0 | 2 | 1 | |||||
| Net debt | — | — | — | 2 | (1) | (16) | (5) | 0 | (10) | (10) | |||||
| Shareholders’ equity | — | — | — | 1 | 1 | 21 | 4 | (7) | 7 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (437.29) | (129.80) | (144.45) | (103.09) | (315.98) | (180.43) | (149.98) | ||||
| ROIC | — | — | — | 0.00 | (3,023.99) | (294.59) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | (1,210.11) | (752.88) | (187.12) | (142.98) | 1,575.62 | (5,650.78) | (450.60) | |||||
Negative figures in brackets.
Charts ten years each
Cingulate Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OSTX OS Therapies Incorporated | $66.0M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| HYFT MindWalk Holdings Corp. | $66.0M | — (loss-making) | — (loss-making) | +19.37% (above 0%: growing) | n/m | +9.79% (above 0%: growing) | 58.58% | (159.86%) | Compare |
| NMAD Nomad Power Solutions, Inc. | $65.9M | — (loss-making) | — | — | n/m | −230.63% (below 0%: shrinking) | — | 0.00% | Compare |
| XBIT XBiotech Inc. | $65.9M | — (loss-making) | — (loss-making) | −93.33% (below 0%: shrinking) | n/m | +25.25% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRO Spero Therapeutics, Inc. | $65.8M | 7.9× | 4.2× | −95.61% (below 0%: shrinking) | n/m | +69.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $64.9M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| CING Cingulate Inc. | $63.8M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | |
| FBIO Fortress Biotech, Inc. | $63.7M | 0.6× | 1.1× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| APLM Apollomics Inc. | $61.2M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | Compare |
| Median of peers | $65.8M | — | — | −53.85% | — | +8.71% | 67.18% | 0.00% |
Cingulate Inc. (CING) key facts
- Cingulate Inc. (CING) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CING traded at $4.33, a market capitalization of $63.8 million.
- Return on equity was −450.6% and debt-to-equity 0.00.
Cingulate Inc. (CING) Latest News
No news at this impact. Lower the threshold for more.